LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2950
-0.0291 (-8.96%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3241
Open0.3340
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2800 - 0.3340
52 Week Range0.2200 - 1.0300
Volume64,601
Avg. Volume117,920
Market Cap23.813M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Lexaria Bioscience Confirms Closing of US$2,039,228 Private Placement

    KELOWNA, BC / ACCESSWIRE / May 11, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today confirms that its private placement financing as previously announced on May 4, 2020 (the "Offering") closed pursuant to two tranches. The Company confirms that it has issued an aggregate 8,028,254 shares ("Shares") of its common stock along with common stock purchase warrants ("Warrants") to purchase up to 8,028,254 shares of its common stock pursuant to the Offering for gross proceeds of US$1,846,498 million in its first tranche closing which occurred on May 6, 2020.

  • ACCESSWIRE

    Lexaria Bioscience Announces Over US$2,000,000 Private Placement

    KELOWNA, BC / ACCESSWIRE / May 4, 2020 / Lexaria Bioscience Corp. (OTCQB:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements with certain qualified investors for the sale of 8,978,260 shares ("Shares") of our common stock along with common stock purchase warrants ("Warrants") to purchase up to 8,978,260 shares of our common stock in a private placement (collectively the "Offering") for gross proceeds of over US$2 million. The purchase price per Share is US$0.23.

  • ACCESSWIRE

    Lexaria Receives Notice of Allowance for New Patent and Awards Stock Options

    KELOWNA, BC / ACCESSWIRE / April 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a new patent which provides additional patent claims that protect the use of its DehydraTECH™ technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. This signifies another addition to Lexaria's first patent family, under which eight US patents have previously been granted.

  • ACCESSWIRE

    Lexaria Bioscience Files New Patent Utilizing DehydraTECH Technology for Treatment of Infectious Diseases Including COVID-19

    KELOWNA, BC / ACCESSWIRE / April 21, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has filed an important new patent application in the United States describing the use of its DehydraTECH™ technology for the delivery of antiviral drugs. The technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. This new patent application includes both method of use and composition of matter claims for the use of Lexaria's DehydraTECH drug delivery technology as a means to increase the bioavailability and, we hypothesize, the effectiveness and tolerability of those oral, lipophilic antiviral drugs that otherwise demonstrate low gastrointestinal uptake and systemic delivery.

  • GlobeNewswire

    Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing

    NEW YORK, March 30, 2020 -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at.

  • GlobeNewswire

    Lexaria Bioscience Corp. to Webcast Live at Life Sciences Investor Forum March 26

    Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platform today announced that Chris Bunka, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on March 26. Investigation into its patented DehydraTECH drug delivery technology will be pursued to determine the extent of improvements possible in antiviral drug delivery designed to fight against coronavirus disease COVID-19.

  • GlobeNewswire

    Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020

    NEW YORK, March 24, 2020 -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry.

  • ACCESSWIRE

    Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories in North America and internationally as soon as possible. Within the Lexaria Pharmaceutical Corp. business unit resides Intellectual Property for enhanced delivery of drugs such as non-steroidal anti-inflammatories ("NSAIDs"), vitamins, hormone treatments utilizing estrogen or testosterone and phosphodiesterase ("PDE5") inhibitors; with expansion now underway to include antiviral drugs as well.

  • ACCESSWIRE

    Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

    KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform for enhancing delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently investigating various antiretroviral drugs as potential candidates to combat COVID-19.

  • ACCESSWIRE

    Lexaria Provides Update on Two Licensed Clients

    KELOWNA, British Columbia / ACCESSWIRE / March 4, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has successfully processed its first DehydraTECHTM-enabled liquid nanoemulsion for cannabidiol ("CBD") beverages for one of its licensed clients. Lexaria's client expects to begin distribution of its line of CBD beverages in select US stores soon. Lexaria's emulsified DehydraTECH processing is an additional service it can now provide to qualifying clients wanting to formulate best in class ready-to-drink beverages containing CBD.

  • ACCESSWIRE

    Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

    KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability for financial savings by industry, solving key industry problems. Both CBD/hemp and cannabis consumers have recently become concerned about potency and safety of the oil extract products they are purchasing. Consumers have legitimate concerns about inventories of hemp or cannabis oil or plant matter being used to create products, and whether their potency is as advertised.

  • ACCESSWIRE

    Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

    KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market, and across all of the US. Cannadips Cannabis Tins are currently sold in California formulated with THC from cannabis. Cannadips recently executed a price adjustment to $14.99 and $24.99 respectively per tin MSRP plus tax in California in order to better align consumer expectations on price with product modality.

  • ACCESSWIRE

    Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

    KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. Cannadips CBD is America's leading and oldest oral pouch, similar to a Snus pouch, formulated with CBD from American hemp. Lexaria, already established as the leader in the CBD oral delivery, has been working with the Boldt Runners team behind the scenes to elevate the product experience.

  • ACCESSWIRE

    Lexaria Provides Strategic Update from CEO

    KELOWNA, BC / ACCESSWIRE / January 9, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the following strategic update. "Lexaria's brightest days lie in the future, not in the past," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. Lexaria achieved many things during 2019 - indeed, management feels that it achieved virtually all that it had set out to accomplish and it was its best year ever from an operational perspective.

  • ACCESSWIRE

    Lexaria’s Technology Now Works in Less Than 10 Minutes

    KELOWNA, BC / ACCESSWIRE / November 21, 2019 / Lexaria Bioscience Corp. (LXRP)(CSE LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECHTM platform that delivers THC onset of action in human pilot testing in less than 10 minutes. In recent human subjective pilot tests, volunteers reported onset of THC action from edibles formulated with this latest DehydraTECH innovation in less than 10 minutes. This enhanced version is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations.

  • ACCESSWIRE

    Lexaria Bioscience Appoints Gregg Smith as Senior Advisor

    KELOWNA, BC / ACCESSWIRE / November 5, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor. Evolution VC is a New York-based "culture tech" venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond Meat, Roman, Sweetgreen, Bird, New Wave Foods, Relativity Space and more. Prior to forming his investment company in 2007, Gregg spent 20 years on Wall Street as an investment banker focused on executing private equity placements with a strong focus on life sciences.

  • ACCESSWIRE

    Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format

    KELOWNA, BC / ACCESSWIRE / October 24, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to report that, for the first time ever, the Food and Drug Administration (the "FDA") has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway, including product categories that could benefit from Lexaria's technology. The product format authorized by the FDA is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed.

  • ACCESSWIRE

    Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria

    KELOWNA, BC / ACCESSWIRE / October 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECHTM technology, underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) ("Altria") and Lexaria's majority owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine"). Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently.

  • ACCESSWIRE

    Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / September 17, 2019 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.

  • GlobeNewswire

    Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery

    While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset.

  • ACCESSWIRE

    Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

    KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 - “Stable ready-to-drink beverage compositions comprising lipophilic active agents”. Lexaria’s patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia. This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” announced on August 15, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.

  • ACCESSWIRE

    Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

    KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECHTM for fast, effective delivery. Long known as a technology innovator, Lexaria delivers patented processes within every serving of ChrgD+ to improve the consumer experience of hemp oil with CBD. ChrgD+ uses the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils.

  • More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media
    Newsfile

    More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media

    Seattle, Washington--(Newsfile Corp. - August 15, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology.When you've got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of ...

  • ACCESSWIRE

    Lexaria Bioscience Announces it has Received Four New Patents

    KELOWNA, BC / ACCESSWIRE / August 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted.

  • ACCESSWIRE

    Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

    KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated. Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing.